Patent · US Active

Extended release formulation of Levetiracetam

US7863316B2 · kind B2 · utility

13Cited by

10References

21Claims

0Family size

Assignee

UCB PHARMA S.A. · BE

Inventors

Rajesh Kshirsagar · Vadodara, IN
Ashwin Rao · Kirkland, US
Nilesh Malaviya · Sayla, IN
Kaustubh Jinturkar · Sayla, IN

Key dates

Filing date	Oct 20, 2006
Grant date	Jan 4, 2011
Priority date	—
Expiry date	Nov 2, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2077
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.